DAPTOMYCIN

Post-LOE

daptomycin

ANDAINTRAVENOUSPOWDER
Approved
Aug 2024
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

12.1 Mechanism of Action Daptomycin is an antibacterial drug [see ]. 12.2 Pharmacodynamics Based on animal models of infection, the antimicrobial activity of daptomycin appears to correlate with the AUC/MIC (area under the concentration-time curve/minimum inhibitory concentration) ratio for certain…

Pharmacologic Class:

Lipopeptide Antibacterial

Clinical Trials (5)

NCT03643952Phase 2Completed

Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)

Started Dec 2018
18 enrolled
BacteremiaSoft Tissue InfectionsSkin Diseases, Infectious
NCT02097953Phase 1Completed

Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin

Started May 2014
12 enrolled
Drug InteractionsPharmacokinetics
NCT01922011Phase 3Completed

Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)

Started Sep 2013
149 enrolled
Acute Hematogenous Osteomyelitis
NCT01728376Phase 4Completed

Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)

Started Nov 2012
Bacteremia
NCT01515020Phase 3Terminated

Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia

Started May 2012
10 enrolled
Nosocomial InfectionHealthcare-associated Infection